Essential Biotechnology

Essential Biotechnology LLC Targets the Core of Cancer with New Antibody Therapy. With the discovery of CRR9, specifically present on the surface of tumor cells, Essential Biotechnology LLC has developed a monoclonal antibody inhibitor of CRR9 (ESS102), which has demonstrated remarkable preclinical anti-tumorigenic effects and resensitization to chemotherapy.